

Our Business Segments

Endo International plc

Headquartered in Dublin, Ireland

\$3.47 billion in revenue in 2017

U.S. Generic Pharmaceuticals

Headquartered in Chestnut Ridge, New York

\$2.28 billion in revenue in 2017

Among the largest U.S. generics company based on market share. Develops, licenses, manufactures, markets and distributes safe, innovative and cost-effective pharmaceuticals with a focus on first-to-file or first-to-market opportunities and high-barrier-to-entry products that are difficult to formulate, difficult to manufacture, or that face complex legal and regulatory challenges. The generics R&D pipeline consists of over 175 products including approximately 100 ANDAs pending with the FDA.

Segment Milestones

- Launched 17 new products including 4 sterile injectable products and the generic version of Sabril® Powder for Oral Solution, a first-to-market generic to launch in the specialty pharmacy market
- Filed 12 regulatory submissions
- Continued strong growth of Sterile Injectables which grew 23% year-over-year
- Continued to restructure our generics manufacturing network to drive greater efficiency

Key Product Lines*

Sterile Injectable Products, New launches/Alternative Dosage Products, Base business

*Note: In February 2018, we made changes to the way we manage and evaluate our business. As a result, our Sterile Injectables portfolio, which was part of our U.S. Generic Pharmaceuticals segment as of December 31, 2017, will be presented as a new segment named U.S. Branded – Sterile Injectables starting in the first-quarter 2018.

U.S. Branded Pharmaceuticals

Headquartered in Malvern, Pennsylvania

\$958 million in revenue in 2017

Focused on developing and marketing high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals' specialty portfolio includes products for urology, men's health, orthopedics and endocrinology, with product development underway in medical aesthetics.

Segment Milestones

- Increased demand for XIAFLEX® in Peyronie's Disease and Dupuytren's Contracture with sales growing 12% in 2017
- Initiated new marketing platforms including customer activation through digital direct-to-consumer outreach to drive further growth of XIAFLEX®
- Enhanced focus on Specialty Branded Pharmaceuticals yielded growth of 11% year-over-year
- Phase 3 design and preliminary launch planning for collagenase clostridium histolyticum (CCH) in cellulite initiated; Two Phase 3 studies commenced in February 2018
- Voluntarily removed OPANA® ER from the market

Key Product Lines

XIAFLEX®, SUPPRELIN® LA, TESTOPEL®, NASCOBAL®, AVEED®

International Pharmaceuticals

\$230 million in revenue in 2017

Our International Pharmaceuticals businesses included: Paladin Labs, headquartered in Montreal, Canada; SOMAR, headquartered in Mexico City, Mexico; and Litha, headquartered in Midrand, South Africa.

Segment Milestones

- Paladin Labs grew 2% year-over-year
- Paladin Labs filed 2 sterile injectables from our existing U.S. portfolio
- Paladin Labs in-licensed ENVARUSUS® for the Canadian market
- Divested non-core International businesses, Litha and Somar in July and October 2017, respectively